<DOC>
	<DOC>NCT00259038</DOC>
	<brief_summary>The study will evaluate the safety and efficacy of intravenous infusion of carperitide using pressure measurements inside the heart and great vessels and measuring carperitide concentration in the blood.</brief_summary>
	<brief_title>Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction, Left</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Is hospitalized with congestive heart failure (CHF) Has a SwanGanz catheter inserted for CHF management and has pulmonary capillary wedge pressure 18 mmHg or higher Has had a heart transplant Requires mechanical ventilation or mechanical circulatory support</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Carperitide</keyword>
	<keyword>Atrial Natriuretic Peptide</keyword>
	<keyword>Treatment efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Heart failure, Congestive</keyword>
	<keyword>Pulmonary Artery Catheterization</keyword>
</DOC>